Anwarbaig C Mirza, Shital S Panchal, Milan Satia, Sanjay N Mandhane, Mohammad Abuzar, Ziyaul Haque
Syringic acid and vanillic acid exhibit significant therapeutic potential owing to diverse pharmacological activities. However, their clinical translation remains limited due to challenges in formulation design, poor bioavailability, and incomplete mechanistic understanding. Future research must focus on advanced drug delivery systems, detailed molecular mechanisms, and well-designed clinical trials to establish them as effective, evidence-based therapeutic agents for human disorders.
INTRODUCTION: Vanillic acid and syringic acid are structurally similar phenolic acids reported to possess significant anti-inflammatory and antioxidant activities. Despite their therapeutic evidence, comparative evaluations of these agents based on molecular mechanisms, pharmacokinetic profiles, and translational potential remain unexplored.
METHOD: A comprehensive literature search was conducted to discover in vitro, in vivo, and in silico studies on syringic acid and vanillic acid by using various search engines such as Pub- Med, Scopus, Web of Science, Google Scholar, and ScienceDirect. Peer-reviewed literature claiming dietary or botanical sources, molecular mechanisms, pharmacokinetics, and structureactivity relationships was included, whereas research not specifically focusing on these compounds was excluded. Scientifically valid data were analyzed and qualitatively examined to compare both their biological function and therapeutic potential.
RESULTS: Syringic acid and vanillic acid exhibit diverse pharmacological actions, preclinical safety, and regulatory acceptability. Available evidence suggests that syringic acid may possess a desirable bioavailability profile with metabolic, vascular, and antioxidant effects, whereas vanillic acid has been reported to exhibit significant anti-inflammatory and antidiabetic effects. Further, syringic acid may be more appropriate for metabolic abnormalities and acute inflammatory conditions, while vanillic acid will be a promising therapeutic agent in hepatic, renal, neurological, and cardiometabolic disorders.
CONCLUSION: Syringic acid and vanillic acid exhibit significant therapeutic potential owing to diverse pharmacological activities. However, their clinical translation remains limited due to challenges in formulation design, poor bioavailability, and incomplete mechanistic understanding. Future research must focus on advanced drug delivery systems, detailed molecular mechanisms, and well-designed clinical trials to establish them as effective, evidence-based therapeutic agents for human disorders.